# Erbitux MEtastatic Colorectal Cancer Strategy Study

> **NCT02484833** · PHASE3 · COMPLETED · sponsor: **Armando Orlandi** · enrollment: 607 (actual)

## Conditions studied

- Antineoplastic Agents

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** FOLFIRI

## Key facts

- **NCT ID:** NCT02484833
- **Lead sponsor:** Armando Orlandi
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2019-12
- **Final completion:** 2020-03
- **Target enrollment:** 607 (ACTUAL)
- **Last updated:** 2020-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02484833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02484833, "Erbitux MEtastatic Colorectal Cancer Strategy Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02484833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*